Expected shareholder recovery
Company: Core Scientific
The claim, verbatim
Common shareholders as of the effective date are expected to receive about $1.18 per pre-exchange share in value, including about $1.11 non-contingent recovery.
Source (primary)
core-scientific 8-K exhibit (d661343dex992.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-13)Live source ↗
Quote: “are expected to receive $1.18 per share of pre-exchange value based on current assumptions”
How we checked this
Checked on November 16, 2026. The cited source supports every part of this claim.
The document says shareholders are expected to receive $1.18 per share of pre-exchange value based on current assumptions. It says this includes a non-contingent recovery of about $1.11 per share.
Confirmed in the source:
- Common shareholders as of the effective date are expected to receive about $1.18 per pre-exchange share in value
- This includes a non-contingent recovery of about $1.11 per share
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312524013078/d661343dex992.htm) in full (29,830 characters, retrieved November 13, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d661343dex992.htm)
Quote: “are expected to receive $1.18 per share of pre-exchange value based on current assumptions”